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Candida species are normal commensal organisms found in the skin, mouth, and
gastrointestinal and genitourinary tracts of humans. Candida albicans is a normal
component of the gut flora, and the oral and genital cavities. However, this organism is
an opportunistic pathogen and it is one of the most frequently isolated species from
patients with nosocomial fungal infections. Candida infections have grown in recent
years due to antimycotics resistance and the extensive use of antibiotics. This has pushed
scientists to look for alternative therapeutic agents to treat fungal infections.
Yeasts can produce toxic proteins called “mycocins” or “killer toxins” that can
kill sensitive yeast species. The production of killer toxins is a phenomenon widely
spread among yeast species. Debaryomyces hansenii, a yeast commonly found in
cheeses, produces killer toxins that are able to kill the strains of Candida albicans
SC5314 and Candida tropicalis NRRL-10985 at optimum conditions of 20C and pH
4.5. The use of Debaryomyces hansenii as a biotechnological agent has been suggested,
but the amount of toxins produced, and the genetic basis and mechanism of action of
these toxins, remains a mystery.

To study the extent of pathogenic Candida species affected by this toxin, nineteen
strains of Debaryomyces hansenii were tested for killer activity against Candida species,
previously isolated from patients with bloodstream infections, by streak-plate agar
diffusion bioassay. The killer activity of Debaryomyces hansenii killer strains was also
tested against Debaryomyces hansenii non-killer strains. Additionally, to understand the
nature of these toxins, 2x250 paired end Illumina sequencing was performed in 6 killer
and 3 non-killer strains of Debaryomyces hansenii previously isolated from different
types of cheeses. Numerous differences among the strains were found. Primers and
protocols were designed to knockout presumptive genes and confirm their relationship
with toxicity.
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“Our greatest weakness lies in giving up. The most certain way to succeed
is always to try just one more time.”
-Thomas A. Edison
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Chapter 1
Killer yeast phenomenon: Debaryomyces hansenii mycocin production
and its applications.

2
1.1 Killer Yeasts
Makower and Bevan first discovered the killer character in Saccharomyces cerevisiae
in 1963 (Woods and Bevan 1968). Killer yeasts produce toxic proteins or glycoproteins
(also called mycocins), and this characteristic has been found in more than 90 yeast
species across more than twenty genera (Table 1.1) (Polonelli et al. 1991; Walker et al.
1995; Young and Yagiu 1978). Killer yeasts are able to kill sensitive yeast species by
several biological pathways and the genetic basis of the killer phenotype can be
chromosomal or cytoplasmic, encoded on double stranded RNA virus-like particles or
linear double stranded DNA plasmids (Magliani et al. 1997). Moreover, as a self defense
mechanism they possess intrinsic immunity to the action of their own mycocins (Schmitt
and Breinig 2002). However, there exist situations where mycocin concentration prevails
and this immunity is overcome, e.g., so-called suicidal mutants (K+ R–) (Polonelli et al.
1991).
Young stated that while all killer systems vary, they have a proteinaceous compound
crucial to the mycocin activity that is common among them, and yeasts from the same
species can produce several toxins with different modes of action (Young and Yagiu
1978). The reason behind killer toxin production is not fully understood; however, it is
possible that killer yeasts produce these components when found in a competitive
ecological niche to ensure survival of the species or strain (Polonelli et al. 1991).
Hodgson agrees with Polonelli and states that these toxins might differ biochemically in
response to ecological interaction with sensitive strains; i.e. killer strains will lose the
ability to generate killer toxins if these are not essential for survival (Hodgson et al.
1995).
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1.2 Killer toxins modes of action
The first step to achieve lethality on a susceptible organism is commonly a cell wall
receptor on the sensitive cell that interacts with the killer toxin (usually chitin, -glucans
or mannoproteins) and suggestions exist about the existence of a second receptor on the
plasma membrane that facilitates absorption (Magliani et al. 1997; Schmitt and Breinig
2006). Subsequently, they can achieve a lethal effect by different biological pathways.
They can induce changes in the permeability of the membrane by forming an ion channel,
leading to uncontrolled leakage of protons, potassium ions, amino acids and ATP
molecules causing cell death (Marquina et al. 2002). Alternatively, they can release
signals that will result in inhibition of DNA synthesis causing a lethal effect (Liu et al.
2015). Several authors explain the relationship between attacking the tRNA and cell
death in the killer activity that Kluyveromyces lactis exhibits towards Saccharomyces
cerevisiae (Frohloff et al. 2001; Jablonowski and Schaffrath 2007; Jablonowski et al.
2006). Additionally, a pathway blocking calcium uptake results in inhibition of cell
growth and division (Liu et al. 2015). Figure 1.1 illustrates several mechanisms of action
of these killer toxins.
Killer toxins are usually temperature and pH dependent (Banjara et al. 2016; Magliani
et al. 1997). Studies show that the common pH for killer toxin stability is between 2.0
and 4.5, and there exist some organisms for which toxin production is irreversibly
inactivated above pH 5.0 (Young and Yagiu 1978).
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Figure 1.1 Schematic of different killer toxins modes of action
(Liu et al. 2015).
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1.2.1 Saccharomyces cerevisiae killer system
Saccharomyces cerevisiae, in which the killer phenomenon was first described, is
the most thoroughly studied killer system. It produces several mycocins: three are
cytoplasmically encoded on dsRNA virus-like molecules (K1, K2 and K28) and two are
encoded on chromosomal DNA (KHS and KHR) (Magliani et al. 1997; Young and Yagiu
1978). Killer yeasts, as a self-protection mechanism, are normally immune to the action
of their own mycocins (Bussey 1991; Schmitt and Breinig 2006). However, S. cerevisiae
killer strains can present themselves as suicidal mutants (killer positive, resistance
negative K+ R–) that produce killer toxins but exhibit a reduced immunity and when
killer toxin concentration is higher than 100-fold it results in a lethal effect, as well as
normal killer strains (K+ R+) and sensitive strains (K- R-) (Polonelli et al. 1991). Neutral
mutants (K– R+) – resistant strains that do not produce killer toxins – also exist (Polonelli
et al. 1991).
K1 toxin (19 kDa) is a disulfide-linked dimer ( and ) that acts on the
susceptible species by a two-step mechanism. First, the toxin binds to the -(16)
glucans on the sensitive strain’s cell wall; this step is dependent on a pH of 4.6. The
second step consist of forming an ion channel that increases the permeability of the
membrane, allowing leakage of protons and potassium ions followed by amino acids and
ATP molecules, resulting in cell death (Bussey 1991; Magliani et al. 1997). K2 toxin
presents the same mode of action as K1 although it is a different two-subunit protein with
a molecular weight of 21.5 kDa. However, killer toxin K28, which forms a heterodimer
and has a molecular weight of 21.5 kDa, possesses a different mode of action. The first
step consists of binding to the -1,3-mannoproteins (Schmitt and Breinig 2002). The
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second step involves stopping DNA synthesis by blocking G1 phase, which provides a
lethal effect (Marquina et al. 2002). The modes of action for toxins KHR and KHS are
unclear, but Magliani indicates the possibility of KHS working by ion-channel formation
similarly to K1 and K2 (Magliani et al. 1997).

1.2.2 Kluyveromyces lactis killer system
Plasmids in yeasts are either dsRNA, circular DNA or linear DNA (Fukuhara
1995). Gunge et al. discovered the Kluyveromyces lactis killer phenotype while searching
for plasmids in yeasts (Gunge et al. 1981). K. lactis killer strains have been found to
exhibit the killer phenotype against several genera and species including Saccharomyces,
Candida and K. lactis non-killer strains (Gunge et al. 1981).
K. lactis possesses two plasmids, pGKL1 and pGKL2, with pGKL2 being
necessary for pGKL1 maintenance and replication. The killer toxin produced by this
organism, as well as the immunity region, are encoded on the linear double stranded
DNA plasmid pGKL1 (Fukuhara 1995). The killer toxin consists of a 156 kDa trimer
(Figure 1.2) with subunits ,  and  (Liu et al. 2015). Four open reading frames (ORFs)
have known functions in pGKL1 (Table 1.4), with ORF2 and ORF4 coding for the
predecessor of the mycocin and ORF3 providing the immunity determinant (Magliani et
al. 1997). The mode of action of this toxin is not well comprehended. However, it is
known that the toxin binds to the chitin component of the cell wall in the susceptible
strain and results in cell cycle arrest at the G1 phase (Magliani et al. 1997).

7

Figure 1.2 Structure of the two plasmids of Kluyveromyces lactis killer system. The
two linear DNA plasmids, pGKL1 and pGKL2, of K. lactis are shown schematically. In
pGKL1, ORF1 is thought to code for a DNA polymerase, ORF2 and 4 for three toxin
subunits ,  and , and ORF3 for immunity (resistance to toxin) determinant; In pGKL2,
ORF2, 4 and 6 are thought to code for a DNA polymerase, a helicase and an RNA
polymerase, respectively; TGF1 has a role in plasmid replication. The terminal proteins
are believed to be covalently attached to the DNA ends. IR, inverted terminal repeats
(Fukuhara 1995).

8
1.2.3 Williopsis mrakii killer system
Williopsis mrakii produces two killer toxins encoded on chromosomal DNA,
namely, HMK and K-500 (Magliani et al. 1997; Marquina et al. 2002). HMK, also
referred to as HK-1, is a 10.7 kDa polypeptide rich in cysteine residues, and disulfide
bonds seem to be the cause of its pH and thermostability; stable at pH 2-11, and at 100C
for 10 min (Magliani et al. 1997). Its killing activity is associated with the inhibition of 1,3-glucan synthesis (Marquina et al. 2002). The second toxin, K-500, is a small
polypeptide, 5.0 kDa, that exhibits killer activity against Candida species presumably by
ion channel formation (Magliani et al. 1997).

1.2.4 Ustilago maydis killer system
The killer character in Ustilago maydis is encoded on dsRNA virus like particles
(Koltin and Day 1976). U. maydis produces three different toxins, KP1, KP4 and KP6,
with the last being the best studied (Finkler et al. 1992). KP6 killer toxin consists of two
polypeptides,  (8.6 kDa) and  (9.1 kDa) (Magliani et al. 1997). Its mechanism of action
is unknown. The  subunit is rich in cysteine and the disulfide bonds are crucial for its
activity, presumably ion channel formation. Furthermore, the  subunit needs to interact
with the cell wall so that the  subunits can cause the lethal effect (Steinlauf et al. 1988).

Table 1.1 Characteristics of the yeast killer toxins (Marquina et al. 2002).
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1.3 Killer toxins applications
Numerous applications for killer yeasts have been proposed over the years (Table
1.2). Scientists have suggested their use as biocontrol agents against wood-decay and
plant pathogenic fungi (Walker et al. 1995). Inhibition of spoilage organisms in the food
industry is an important application that has been widely studied (Palpacelli et al. 1991),
and special attention has been given within the wine industry due to the low pH required
for the killing activity to occur (Heard and Fleet 1987; Jacobs et al. 1988; Tredoux et al.
1986). Santos looked at PMKT2 killer toxin produced by Pichia membranifaciens
(Santos et al. 2009), and KP6 killer toxin produced by Ustilago maydis (Santos et al.
2011) and demonstrated the potential of both organisms as biocontrol agents to inhibit the
growth of the spoilage yeast Brettanomyces bruxellensis in wine fermentations, due to the
resistance that Saccharomyces cerevisiae exhibits towards these toxins. Also, he studied
inhibition of Botrytis cinerea (a mold) by P. membranifaciens killer toxin in apples
(Santos et al. 2004), and proposed its use as a biological control. The yeast Williopsis
saturnus var. saturnus, which is incapable of fermenting lactose and/or galactose, was
investigated for its potential as a biopreservative in cheese (Liu and Tsao 2009). Even
inhibition of pathogenic bacteria like Listeria monocytogenes by food-borne yeasts has
been investigated (Goerges et al. 2006).
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Table 1.2 Potential applications of killer toxins.
Biotechnological field of

Application

application
Biological control in agriculture

Antifungal activity against wood-decay and plant
pathogenic fungi. Prevention of aerobic spoilage of
silage.

Beverage fermentation

Avoid undesired contamination in wine, beer, sake,
etc.

Cellular biology research on

Studies of biosynthesis, cellular processing and

eukaryotic cells

secretion of proteins.

Food technology

Food preservatives of natural origin.

Genetics

Selection of hybrids obtained by protoplast fusion.
Fingerprinting of wine yeasts. Recombinant DNA
technology (cloning vectors).

Medicine

Killer activities against pathogenic yeasts.

Taxonomy

Killer toxin sensitivity patterns may be indicative
of phylogenetic affiliation.

Source (Marquina et al. 2002)

Moreover, researchers that have found killer activity against human pathogenic
strains have encouraged the study of these organisms for the possible treatment of
diseases (Banjara et al. 2016; Liu et al. 2015; Polonelli et al. 1986). The antifungal drug
amphotericin B that is used to treat yeast infections (Vyas and Gupta 2006) induces
permeability of ions through the membrane when used at high concentrations, which
causes the antifungal antibiotic effect (Polonelli et al. 1991). This is similar to the mode
of action of some killer toxins. Antifungal therapy against yeast infections can be
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ineffective due to emerging resistance, and more treatment options are needed due to
the increase in nosocomial infections among immunocompromised patients (Sobel 2006).

1.4 Debaryomyces hansenii
Debaryomyces hansenii (also identified in the literature as Candida famata, although
it is probably a distinct but closely related species (Dmytruk and Sibirny 2012)) is a
haploid yeast that reproduces by multilateral budding (Breuer and Harms 2006). It
possesses many characteristics that make it an important yeast for biotechnological
applications. The ability to synthesize and accumulate lipids, making it a so-called
oleaginous yeast, has been studied by several scientists (Merdinger and Devine 1965;
Tunblad-Johansson et al. 1987). The synthesis of D-arabitinol (Anderson and Harris
1963) and the capability to use inorganic ammonium as a nitrogen source (Breuer and
Harms 2006; Yanai et al. 1994) are commercially attractive. D. hansenii produces large
quantities of xylitol (Parajó et al. 1997; Roseiro et al. 1991), a sugar alcohol used in
sugar-free foods due to its intense sweet taste (Sardesai and Waldshan 1991), diabetics’
tolerance towards it, and anti-cavity properties (Isokangas et al. 1988). It also produces
volatile compounds that are favorable for flavor development in dry-cured meat products
(Andrade et al. 2010) and cheeses (Gori et al. 2012). Moreover, D. hansenii is an
extremophile, one of the most halotolerant yeast species, growing in media containing up
to 4M NaCl (Breuer and Harms 2006). It was originally isolated from saline
environments (Kumar et al. 2012) and is among the most common yeasts found in cheese
(Banjara et al. 2015) and in dry–cured meat products (Andrade et al. 2009). D. hansenii
can also be found in environments with low water activity; hence its association with soil,
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fruits, wine and beer (Breuer and Harms 2006; Kumar et al. 2012). D. hansenii exhibits
considerable genetic diversity between strains (Corredor et al. 2003), reflected in the
number of carbon substrates for which assimilation is denoted “variable” (Table 1.3). D.
hansenii grows poorly in anaerobic conditions, contributing to the inability of some
strains to ferment lactose, and leading to weak fermentation of galactose, sucrose,
glucose, maltose and raffinose (Breuer and Harms 2006).
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Table 1.3 Assimilation of substrates by Debaryomyces hansenii.
Glucose

+

N-Acetyl-D-glucosamine

V

Galactose

+

Methanol

L-Sorbose

V

Ethanol

+/W

Sucrose

+

Glycerol

+

Maltose

+

Erythritol

V

Cellobiose

+

Ribitol

+

Trehalose

+

Galacitol

V

Lactose

V

D-Mannitol

+

Melibiose

V

D-Glucitol

+/W

Raffinose

+

-Methyl-D-glucoside

Melezitose

V

Salicin

+/W

Inulin

V

D-Gluconate

+/W

Soluble starch

V

DL-Lactate

V

D-Xylose

+

Succinate

+

–

+

L-Arabinose

+/W

Citrate

V

D-Arabinose

V

Inositol

–

D-Ribose

V

Hexadecan

V

L-Rhamnose

V

Nitrate

–

D-Glucosamine

V

Nitrite

V

2-Keto-D-gluconate

+

5-Keto-D-gluconate

V

Saccharate

–

+ = positive, W = weak, V = variable, – = negative
Source (Breuer and Harms 2006)
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1.4.1 Debaryomyces hansenii killer toxin production
Strains of Debaryomyces hansenii exhibit the killer phenotype and have been
found to tolerate killer toxins from Kluyveromyces lactis, Candida zeylanoides and
Trichosporon cutaneum (Fukuhara 1995; Nout et al. 1997). This suggests possible
applications in food fermentations and preservation (Santos et al. 2002) and as a
therapeutic agent (Banjara et al. 2016; Buzzini and Martini 2001). The genetic basis of
the killer activity in Debaryomyces hansenii is unknown. Gunge reported the presence of
three plasmids, pDHL1, pDHL2 and pDHL3, in D. hansenii (Gunge et al. 1993). Linear
plasmid pDHL3 is essential for the replication of plasmids pDHL1 and pDHL2 (Fukuda
et al. 1997). Plasmid pDHL1 is highly homologous to the plasmid pGKL1 present in
Kluyveromyces lactis (Table 1.4), in which the linear dsDNA plasmid pGKL1 encodes a
protein that is responsible for the killer phenotype (Fukuda et al. 1997; Gunge et al. 1993;
Magliani et al. 1997). Santos and Marquina (Santos et al. 2002) were unable to eliminate
the killer phenotype with various treatments used to eliminate plasmids (exposure to high
temperatures, ultraviolet light and cycloheximide) and therefore concluded that the killer
factor is chromosomally encoded. They reported that the killer toxin is a low molecular
weight secreted protein, and identified 16--D-glucan as the cell wall binding site for
this killer toxin. However, it is unknown if additional toxins may exist, as is the case of
Saccharomyces cerevisiae, or how the killing mechanism of any of these toxins is
achieved.
Corredor and colleagues reported high genome variability between strains of
Debaryomyces hansenii based on chromosomal rearrangements and repeated and deleted
sequences (Corredor et al. 2003). Banjara’s work agrees with Corredor’s findings, in so
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far as D. hansenii isolates from cheese showed consistent, reproducible variation in
killer toxin activity, suggesting genetic differences between them. Furthermore, his work
confirmed reports from Marquina and colleagues (Marquina et al. 2001), where it was
revealed that the killer activity is pH and temperature dependent with optimum conditions
at 20C and pH 4.5, and extended the findings to multiple D. hansenii strains (Banjara et
al. 2016).
Mycocins produced by the cheese-derived yeast Debaryomyces hansenii represent
an interesting area of research due to their ability to kill human fungal pathogens Candida
albicans and Candida tropicalis in vitro. It is evident that more research is needed to
understand the mechanisms by which these mycocins kill Candida species, so as to be
able to use them as therapeutic agents for the possible treatment of fungal infections.

Table 1.4 Relatedness of gene sequences of the linear plasmids vs. K. lactis killer plasmids (Fukuhara 1995).
pGKL1 gene probes
Host

K. lactis

W. robert.

D. hansen.

P. etchel.

Plasmid

pGKL2 gene probes

ORF1

ORF2a

ORF2

ORF3

ORF4

ORF2

ORF6

(DNA pol)

(toxin )

(tox.  + )

(immun.)

(toxin )

(DNA pol)

(RNA pol)

pKL2A

+++

+++

+++

+++

+++

–

–

pKL2B

–

–

–

–

–

+++

+++

pWR1A

–

+

+

–

–

–

–

pWR1B

–

–

–

–

–

+

+

pDH1A

+

+

+

–

–

–

–

pDH1B

–

–

–

–

–

+

+

pPE1A

–

–

–

–

–

–

–

pPE1B

–

–

–

–

–

–

+

Three pairs of linear plasmid DNAs were examined for the presence of homology with K. lactis killer DNA genes. Each DNA was
hybridized with labeled individual gene probes from the K. lactis killer plasmids pGKL1 and 2. Data were taken from (Cong et al.
1994); + and – indicate presence and absence of hybrid signals, respectively. + + + corresponds to the intense signal of homologous
hybridization at the same stringency condition. ORF2a is the N-terminal half of ORF2, coding for the toxin subunit . K. lactis =
Kluyveromyces lactis, W. robert = Wingea robertsiae, D. hansen = Debaryomyces hansenii, P. etchel = Pichia etchellsii.
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1.5 Candida species as human pathogens
Candida species are commensal yeasts of the human skin, mouth, gut, and vagina
(Figure 1.3) that usually cause no harm in healthy individuals. However, when the host
system is altered, i.e. the immune system is suppressed, they take advantage and become
pathogenic (see Table 1.5 for risk factors). Infections caused by Candida yeasts (known
as candidiasis) can range from mild cutaneous lesions and mucosal infections to severe
systemic infections (bloodstream infections, i.e., candidemia, and invasive candidiasis,
[IC]). Candida albicans is the most commonly isolated pathogenic species from
infections, but there are other clinically important species such as C. glabrata, C.
parapsilosis, C. krusei and C. tropicalis, which are also frequently found in patients with
fungal infections (Papon et al. 2013; Suhr 2015). Candida is the most common cause of
hospital-acquired fungal infections (see Table 1.7 for species breakdown) and is
responsible for up to 40% mortality rate (Alonso-Valle et al. 2003). The incidence of
yeast infections continues to increase every year (Table 1.6), probably due to the
extensive use of antibiotics and an increasing population of immunosuppressed
individuals. Additionally, drug-resistant species and strains are increasing in prevalence
(Sobel 2006). Hence, biological controls constitute a valuable possibility for the
treatment of these diseases.
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Table 1.5 Major risk factors for invasive Candida infections (Perlroth et al. 2007).
Iatrogenic/Nosocomial Conditions* Immunosuppression*
Colonization

Neutropenia

Broad spectrum antibiotics

Corticosteroids

Central venous catheter

HIV‡

Parenteral nutrition

Diabetes mellitus‡

Gastrointestinal or cardiac surgery
Prolonged hospital stay†
ICU stay
Burns
Premature neonate
*Many iatrogenic/nosocomial conditions are accompanied by poorly
characterized immune defects (e.g., burn injuries and surgery down
modulate normal host defense mechanisms), as is diabetes mellitus.
‡HIV and diabetes mellitus predominantly predispose to mucocutaneous
candidal infections, and diabetes is also a risk factor for disseminated
disease; HIV is a cofactor for, but not an independent risk factor for,
disseminated disease.
†Mean time to onset of disease in a recent, large, prospective study was
day 22 of hospitalization.

20
Table 1.6 Trends in bloodstream infections caused by yeasts (Hazen 1995).
Year of
Review
1985

Summary and comments

Reference

Studied only candidemia; frequency of species was C.

(Horn et al.

albicans > C. tropicalis > C. parapsilosis > C. glabrata >

1985)

C. krusei > other species
1986

Concerned with Virginia hospitals; found increase in

(Morrison et

Candida infections between 1978 and 1984 from 0.1 to 1.5

al. 1986)

cases/10,000 patient discharges
1989

Ranked nosocomial bloodstream infections; from 1984 to

(Pfaller 1989)

1988, Candida species changed from eight to fourth most
common agent of infection; genera of gram-negative bacilli
are considered as individual categories
1991

Candida species are fifth leading cause of bloodstream

(Banerjee et

infection in 1989 (up from sixth in 1980) if gram-negative

al. 1991)

bacilli are considered one group
1991

Survey on fungemia for 1989 in one hospital in South

(Badenhorst

Africa found that 2.1% of blood cultures contained yeasts;

et al. 1991)

these included C. albicans (42%), C. tropicalis (26%),
C. parapsilosis (20%), C. glabrata (7%), Hansenula spp.
(2%), C. guilliermondii (1%), and C. krusei (1%).
1992

Retrospective study in Indian teaching hospital; compared

(Chakrabarti

5-yr periods 1980-1985 and 1986-1990; found 11-fold

et al. 1992)

increase in candidemia; most common species isolated
were C. albicans, C. tropicalis, C. parapsilosis, and
C. guilliermondii
1992

Fungemia isolates in one hospital between 1984 and 1990;

(Meunier et

C. albicans > C. tropicalis = C. glabrata > C. krusei >

al. 1992)

C. parapsilosis = C. guilliermondii
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Figure 1.3 The human mycobiota (Underhill and Iliev 2014).
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Table 1.7 Species breakdown of disseminated candidiasis (Perlroth et al. 2007).
Species

Percent of cases

Candida albicans

≈ 50%

Candida glabrata

≈ 15 – 25%

Candida parapsilosis ≈10 – 20%
Candida tropicalis

≈ 15%

Candida krusei*

≈ <3%

Others

≈ <5%

*At cancer centers where significant fluconazole prophylaxis is used, C. krusei
incidence may cause up to 10 – 15% of disseminated candidiasis.

1.5.1 Candida albicans
Candida albicans is the most commonly isolated species from patients with
invasive infections, being responsible for 50% of Candida infections (Perlroth et al.
2007). It possesses a range of virulence factors (dimorphism, adhesins and invasins,
formation of biofilms, secretion of hydrolytic enzymes) and fitness attributes (rapid
stress, pH change and nutrient deficit adaptation) that account for its pathogenicity
(Mayer et al. 2013). Dimorphism is the ability of the organism to change from a yeast
form to hyphal form (Jacobsen et al. 2012). The yeast disseminates through the body and
subsequently the formation of the hyphae expresses genes that encode for virulence
factors (Mayer et al. 2013). Adhesins are proteins that facilitate the adherence of C.
albicans to the cell surface, which is the first step towards infection (Garcia et al. 2011;
Tsai et al. 2013). There are three different hydrolases produced by C. albicans: lipases,
phospholipases and proteases (Williams et al. 2013). These hydrolytic enzymes help to
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disseminate the infection (Wächtler et al. 2012) and in nutrient acquisition (Naglik et
al. 2003). Additionally, biofilm formation is an important virulence factor. Biofilms are
resistant to antimicrobials and antifungals, and the accumulation of yeast cells in medical
equipment, e.g., catheters, present a serious risk for immunocompromised patients
(Fanning and Mitchell 2012).

1.5.2 Candida glabrata
Candida glabrata is the second most common Candida species isolated from
patients with candidemia in the US and Europe, accounting for 15 – 25% of Candida
infections (Perlroth et al. 2007; Pfaller et al. 1998). It is closely related to Saccharomyces
cerevisiae, unlike other Candida species (Roetzer et al. 2011). C. glabrata infections are
more common in adults and are associated with azole prophylaxis, surgery and catheters
(Krcmery and Barnes 2002). C. glabrata is resistant to azoles, which are the most
commonly used antifungals due to their effectiveness against other Candida species.
However, it is vulnerable to other antifungals like amphotericin B (Fidel et al. 1999).

1.5.3 Candida tropicalis
Candida tropicalis is responsible for 10 – 20% of Candida infections (Perlroth et
al. 2007). It is among the most common non-Candida albicans Candida (NCAC) species
isolated from infections (Negri et al. 2011) and it has been presenting resistance to
fluconazole (Kothavade et al. 2010). Taxonomically speaking C. tropicalis is closely
related to C. albicans (Negri et al. 2011). The rate of infections is correlated with several
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risk factors including cancer, antibiotics, prolonged stay in hospitals, neutropenia and
bone marrow transplants (Krcmery and Barnes 2002; Negri et al. 2011).

1.5.4 Candida parapsilosis
Candida parapsilosis accounts for 10 – 20% of Candida infections (Perlroth et al.
2007). Infections are a threat mostly to neonates and are related to hyperalimentation and
body insertions (catheters) (Kojic and Darouiche 2004; Silva et al. 2012).

1.6 Anti-Candida activity by killer yeasts
Killer yeasts are known to have antimicrobial effects over sensitive species.
Williopsis mrakii, Hanseniaspora uvarum and Hansenula anomala are a few of the yeast
that exhibit anti-candida activity (Hodgson et al. 1995; Schmitt et al. 1997). More
recently, killer toxin produced by marine-derived yeast Wickerhamomyces anomalus has
been found to produce killer toxins against C. albicans and C. tropicalis at pH 3.5 and
16C (Guo et al. 2013), and food-derived yeast Debaryomyces hansenii has been found to
produce killer toxins against C. albicans and C. tropicalis at pH 4.5 and 20C (Banjara et
al. 2016). Killer toxins depend on pH and temperature for their action, and these differ
between species; being prevalent low pH and temperature (~20C) for the killing activity.
Most of the studies in killer yeasts have been performed in vitro, especially those
against Candida species. Killing in vivo has not yet been reported. The human body
temperature is 37C and due to the low temperature needed for the killing activity of
mycocins to occur, the therapeutic use of these toxins in vivo presents a challenge. To be
able to use killer toxins as antifungals, the toxin would need to overcome several
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obstacles, including being active at 37C, surviving the acidity of the stomach and
finally reaching the lower gastrointestinal tract, which is where most of the drugs are
absorbed (Martinez and Amidon 2002).
Nonetheless, this presents itself as an important research field. The extensive use of
antibiotics, the increase in the number of immunocompromised patients and the amount
of pathogens becoming resistant to antifungals are some of the reasons why yeast
infections are continuing to increase every year (Hazen 1995; Pfaller 1989; Sobel 2006).
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Chapter 2
Effect of Debaryomyces hansenii killer toxin against pathogenic
bloodstream Candida isolates.
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2.1 Abstract
Candida species are commensal organisms (part of the normal human
microbiota), but when the host immune system is disrupted they can become pathogenic.
Antifungal therapy against yeast infections can be ineffective due to emerging resistance
correlated with their prolonged use, and more treatment options are needed. Yeast
production of toxic proteins or glycoproteins, i.e. killer toxins or mycocins, was first
discovered in Saccharomyces cerevisiae, and it has been observed in more than 90
species. One of the applications of killer toxins is in the field of biotechnology, as is the
case for Debaryomyces hansenii, which was found to produce toxins against common
human fungal pathogens Candida albicans (SC5314) and Candida tropicalis (NRRL10985). However, the extent of yeast species and strains susceptible to D. hansenii’s
toxin(s), and the nature of this susceptibility, remain unknown. To expand the knowledge
on the extent of pathogenic Candida species susceptible to Debaryomyces hansenii killer
toxin, nineteen D. hansenii strains were assayed for killer activity against nine
bloodstream isolates from six pathogenic yeast species. No strain had any effect on
bloodstream Candida albicans, Candida parapsilosis or Candida orthopsilosis under the
conditions tested. The single Wickerhamomyces anomalus strain was susceptible to the
same D. hansenii strains that killed Candida tropicalis NRRL-10985, and Candida
glabrata presented an unusual, but very interesting susceptibility pattern. Additionally, D.
hansenii strains were assayed for killing activity against each other, with no such activity
detected. Finally, protein biosynthesis was inhibited with cycloheximide so as to
investigate whether the toxin was coded cytoplasmically or chromosomally. Killer toxin
assay on samples treated with cycloheximide suggests that the toxin is encoded in the
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chromosome (instead of cytoplasmically) and that there exist numerous differences
between D. hansenii strains that may account for the difference in toxicity.

2.2 Introduction
Candida species are commensal yeasts of the human skin, mouth, gut and vagina,
usually causing no harm in healthy individuals. However, when the host system is
altered, i.e. the immune system is suppressed, they take advantage and become
pathogenic. Infections caused by Candida yeasts (known as candidiasis) can range from
mild cutaneous lesions and mucosal infections to severe systemic infections (bloodstream
infections, i.e., candidemia, and invasive candidiasis, [IC]). Candida albicans is the most
commonly isolated pathogenic species from infections, but there are other clinically
important species such as C. glabrata, C. parapsilosis, C. krusei and C. tropicalis, which
are also frequently found in patients with fungal infections (Papon et al. 2013; Suhr
2015). The incidence of yeast infections continues to increase every year, probably due to
the extensive use of antibiotics and an increasing population of immunosuppressed
individuals. Additionally, drug-resistant species and strains are increasing in prevalence
(Sobel 2006). Hence, biological controls constitute a valuable possibility for the
treatment of these diseases.
Makower and Bevan first discovered the killer character in Saccharomyces
cerevisiae in 1963 (Woods and Bevan 1968). Killer yeasts produce toxic proteins or
glycoproteins (also called mycocins), and this characteristic has been found in more than
90 yeast species (Buzzini and Martini 2001; Young and Yagiu 1978). Killer yeasts are
able to kill sensitive yeast species and they possess intrinsic immunity to the action of
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their own mycocin (Schmitt and Breinig 2002). The genetic basis of the killer
phenotype varies; it can be chromosomal or cytoplasmic (viral dsRNA or linear dsDNA
plasmids). Killer yeasts can produce more than one toxin, as is the case for the best
studied organism Saccharomyces cerevisiae, which produces 5 different toxins: K1, K2
and K28, which are cytoplasmically encoded (viral dsRNA) and KHR and KHS which
are encoded on chromosomal DNA (Magliani et al. 1997). The mechanism of action by
which these mycocins kill sensitive species varies. It has been shown that they can do so
by inhibiting DNA replication, inducing changes in membrane permeability (pore
formation) or by cell cycle arrest in G1 phase, among others (Liu et al. 2015).
Debaryomyces hansenii is a haploid yeast that reproduces primarily by budding. It
can be found in environments with low water activity and it is one of the most
halotolerant yeast species (up to 25% NaCl); hence its association with cheese, meat, soil,
wine and beer (Breuer and Harms 2006; Kumar et al. 2012). D. hansenii exhibits the
killer phenotype and it has been found to produce and tolerate killer toxins (Banjara et al.
2016; Breuer and Harms 2006; Santos et al. 2002). This characteristic suggests possible
applications in food fermentations and preservation (Santos et al. 2002) and as a
therapeutic agent (Banjara et al. 2016; Buzzini and Martini 2001).
The genetic basis of the killer activity in Debaryomyces hansenii is unknown.
Gunge reported the presence of plasmids, pDHL, in D. hansenii, but studies show that the
killer activity is not associated with this plasmid; while in Kluyveromyces lactis, a linear
dsDNA plasmid encodes the killer phenotype (Fukuda et al. 1997; Gunge et al. 1993).
Santos and Marquina (Santos et al. 2002) reported that the killer toxin is a low molecular
weight secreted protein encoded in chromosomal DNA, and identified 16--D-glucan
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as the cell wall binding site for this killer toxin. However, it is unknown if additional
toxins may exist, as is the case of Saccharomyces cerevisiae, or how the killing
mechanism of these toxins is achieved.
Corredor and colleagues reported high genome variability between strains of
Debaryomyces hansenii based on chromosomal rearrangements and repeated and deleted
sequences (Corredor et al. 2003). Banjara’s work agrees with Corredor’s findings, in so
far as D. hansenii isolates from cheese showed consistent, reproducible variation in killer
toxin activity, suggesting genetic differences between them. Furthermore, his work
confirmed reports from Marquina and colleagues (Marquina et al. 2001), where it was
revealed that the killer activity is pH and temperature dependent, with optimum
conditions at 20C and pH 4.5, and extended the findings to multiple D. hansenii strains
(Banjara et al. 2016).
Mycocins produced by the cheese-derived yeast, Debaryomyces hansenii,
represent an interesting research field due to their ease of isolation and ability to kill
human fungal pathogens Candida albicans and Candida tropicalis in vitro. It is evident
that more research is needed to understand the breadth of action of these mycocins
against Candida species, so as to be able to use them as antifungal therapeutic agents for
the possible treatment of these infections. In this study, we intend to broaden the
knowledge on the diversity of infectious species and strains affected by this toxin,
executing in vitro assays using previously isolated pathogenic Candida from bloodstream
infections.
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2.3 Materials and Methods
Fungal Strains, growth media and culture conditions
YEPD rich media (1% yeast extract, 2% peptone, 2% dextrose) was used to grow
nineteen strains of Debaryomyces hansenii (Table 2.1), previously isolated from a
variety of cheeses (Banjara et al. 2016), at room temperature. Strains were designated
“killer” or “non-killer” based on killer activity against Candida albicans SC5314 and C.
tropicalis NRRL 10985 (Banjara et al. 2016). Human pathogenic yeast strains were
grown in YEPD at a temperature of 37C (Table 2.2). All yeasts were maintained on
YEPD slants at room temperature, and at -86C in 35% glycerol.

Table 2.1 Debaryomyces hansenii strains and their source of isolation (Banjara et al.
2016).
Strain ID
Dhans-10
Dhans-34
Dhans-45
Dhans-46
Dhans-65
Dhans-68
Dhans-72
Dhans-75
Dhans-76
Dhans-201
Dhans-220
Dhans-237
Dhans-242
Dhans-246
Dhans-255
Dhans-262
Dhans-265

Cheese
Queso Authentico
Italian Bel Pase
Belgioloso Romano
Wisconsin Roth Kase
Landana 1000 days (Gouda)
Queso Authentico
Hennings Colby
Italian Belpase
Cheddar (Black Creek Smooth and Creamy)
Bavarian Red (Rougetta)
Italian Bel Paese (Galbani)
Italian Bel Paese
Parmesan (Reggiano)
Raclette (Grand Cru)
Provolone Cheese (Dilusso’s Wisconsin)
Ricotta
Wensleydale cheese (Coombe castle)

Killer phenotype
+
+
+
+
+
–
–
–
–
+
+
+
+
+
+
+
+
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Dhans-274
Dhans-276
CBS 767

Blue cheese (Roth Kase Minis)
Blue cheese (Roth Kase Minis)
Sequenced strain
(http://genolevures.org/deha.html)

+
+

Table 2.2 Pathogenic strains and source of isolation (Suhr 2015).
Pathogenic species
Candida albicans
Candida albicans
Candida albicans
Candida tropicalis
Candida parapsilosis
Candida parapsilosis
Candida parapsilosis
Candida parapsilosis
Candida orthopsilosis
Candida glabrata
Wickerhamomyces anomalus

Strain ID
SC5314
B1783
B4549
NRRL-10985
B0595
B9860
B9832
B4075
B4791
B9872
B1448

Source of Isolation
Laboratory strain
Blood
Blood
Laboratory Strain
Blood
Blood
Blood
Blood
Blood
Blood
Blood

Killer toxin activity assays
Killer toxin activity of Debaryomyces hansenii killer strains was evaluated against
pathogenic species and strains (see Table 2.2 for pathogenic strains), and against nonkiller D. hansenii strains. Killer toxin activity was determined using the streak-plate agar
diffusion bioassay (Hodgson et al. 1995; Rosini 1983). YEPD-methylene blue agar (1%
yeast extract, 2% peptone, 2% dextrose, 2% agar, 0.003% methylene blue and 10mM
sodium citrate) was prepared, and pH was adjusted to 4.5 with HCl. The media was
autoclaved and cooled to 45C. Subsequently, it was seeded with pathogenic or D.
hansenii strains to a final density of 105 cells ml-1. Ultimately, 15 ml were poured into
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each plate and after 5 hours, colonies of D. hansenii were streaked on the surface of the
agar. Plates were incubated at 20C and examined daily. Toxin production, a killer
positive reaction, was determined visually by the presence of an inhibition zone (see
Figure 2.1), whereas the absence of the inhibition zone indicated lack of killer activity
(Hernández et al. 2008).

Cold shock killer toxin assay
Killer toxin activity of Debaryomyces hansenii strains was evaluated against
pathogenic species by streak-plate agar diffusion bioassay (Hodgson et al. 1995; Rosini
1983). YEPD-methylene blue agar (1% yeast extract, 2% peptone, 2% dextrose, 2% agar,
0.003% methylene blue and 10mM sodium citrate) was prepared, and pH was adjusted to
4.5 with HCl. The media was autoclaved and cooled to 45C. Subsequently, it was
seeded with pathogenic strains to a final density of 105 cells ml-1. 15 ml were poured into
each plate and after 5 hours, colonies of D. hansenii were streaked on the surface of the
agar. Plates were incubated at 10C for 24 hours and then placed at 20C. Indication of
toxin production was evaluated as previously described.

Plasmid curing
Debaryomyces hansenii killer strains were grown at room temperature in YEPD
media (1% yeast extract, 2% peptone and 2% dextrose) containing cycloheximide at
concentrations of 1 mg ml-1 and 10 mg ml-1. Alternatively, YEPD-methylene blue agar
(1% yeast extract, 2% peptone, 2% dextrose, 2% agar, 0.003% methylene blue and
10mM sodium citrate) was prepared and pH was adjusted to 4.5 with HCl (Santos et al.
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2002). The media was autoclaved and cooled to 45C. Subsequently, it was seeded
with Candida albicans SC5314 and Candida tropicalis NRRL-10985 to a final density of
105 cells ml-1 and cycloheximide at concentrations of 1 mg ml-1 and 10 mg ml-1 was
added. Ultimately, 15 ml were poured into each plate and after 5 hours, colonies of D.
hansenii (Dhans-237, Dhans-276 and CBS 767) were streaked on the surface of the agar
and incubated at 20C. Indication of toxin production was evaluated as previously
described.

2.4 Results and Discussion
From nineteen cheese-derived Debaryomyces hansenii strains, Banjara and
colleagues (2016) reported fifteen strains with killing activity and four strains which
consistently do not exhibit the killer phenotype (Table 2.1). However, they only tested
killer activity against a single strain each of Candida albicans and Candida tropicalis. To
expand the knowledge on the extent of pathogenic Candida species susceptible to
Debaryomyces hansenii killer toxin, we reproduced Banjara’s assays against Candida
albicans SC5314 and Candida tropicalis NRRL-10985, and additionally tested nine
pathogenic Candida strains previously isolated from small bowel transplant patients with
bloodstream infections (Suhr 2015). Our results mostly confirmed Banjara’s on C.
albicans SC5314 and C. tropicalis NRRL-10985, with C. tropicalis more sensitive than
C. albicans; however, strain Dhans-255 failed to kill C. tropicalis in our studies.
Interestingly, Dhans-255 is morphologically distinct, having a rough surface when grown
on solid culture medium, whereas the rest of the D. hansenii strains appear smooth. No
D. hansenii strain exhibited killing activity against bloodstream isolates of Candida

46
albicans (B1783 and B4549), Candida parapsilosis (B9860, B0595, B9832 and
B4075) and Candida orthopsilosis B4791. However, the bloodstream isolate of
Wickerhamomyces anomalus (B1448) displayed the same sensitivity profile as Candida
tropicalis NRRL-10985 (Table 2.3 and Table 2.4).
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a
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Inhibition

b

Figure 2.1 Killer assay. YPD methylene blue plate agar seeded with Candida tropicalis
NRRL-10985 and then streaked with killer and non-killer strains of Debaryomyces
hansenii. Killer strains (a) show a zone of inhibition after 24 hours of incubation at 20C,
as opposed to non-killer strains (b) where no inhibition zone is observed.

Table 2.3 Killer toxin activity against pathogenic species at 20C.
Strain

Candida albicans
Candida parapsilosis
C. ortho C. glab
C. trop
W. anom
SC5314 B1783 B4549 B9860 B0595 B9832 B4075
B4791
B9872 NRRL-10985
B1448
Dhans-10
+
–
–
–
–
–
–
–
–
+
+
Dhans-34
+
–
–
–
–
–
–
–
–
+
+
Dhans-45
+
–
–
–
–
–
–
–
–
+
+
Dhans-46
+
–
–
–
–
–
–
–
–
+
+
Dhans-65
+
–
–
–
–
–
–
–
–
+
+
Dhans-68
–
–
–
–
–
–
–
–
–
–
–
Dhans-72
–
–
–
–
–
–
–
–
–
–
–
Dhans-75
–
–
–
–
–
–
–
–
–
–
–
Dhans-76
–
–
–
–
–
–
–
–
–
–
–
Dhans-201
+
–
–
–
–
–
–
–
–
+
+
Dhans-220
+
–
–
–
–
–
–
–
–
+
+
Dhans-237
+
–
–
–
–
–
–
–
–
+
+
Dhans-242
+
–
–
–
–
–
–
–
–
+
+
Dhans-246
+
–
–
–
–
–
–
–
–
+
+
Dhans-255
+
–
–
–
–
–
–
–
–
–
–
Dhans-262
+
–
–
–
–
–
–
–
–
+
+
Dhans-265
+
–
–
–
–
–
–
–
–
+
+
Dhans-274
+
–
–
–
–
–
–
–
–
+
+
Dhans-276
+
–
–
–
–
–
–
–
–
+
+
C. ortho = Candida orthopsilosis, C. glab = Candida glabrata, C. trop = Candida tropicalis, W. anom = Wickerhamomyces anomalus
+ = Killer positive, presence of an inhibition zone
– = Killer negative, no inhibition zone observed
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Table 2.4 Killer toxin activity against pathogenic species after 24 hour cold shock.
Strain

Candida albicans
Candida parapsilosis
C. ortho C. glab
C. trop
W. anom
SC5314 B1783 B4549 B9860 B0595 B9832 B4075
B4791
B9872 NRRL-10985
B1448
Dhans-10
+
–
–
–
–
–
–
–
–
+
+
Dhans-34
+
–
–
–
–
–
–
–
v
+
+
Dhans-45
+
–
–
–
–
–
–
–
+
+
+
Dhans-46
+
–
–
–
–
–
–
–
–
+
+
Dhans-65
+
–
–
–
–
–
–
–
+
+
+
Dhans-68
–
–
–
–
–
–
–
–
–
–
–
Dhans-72
–
–
–
–
–
–
–
–
–
–
–
Dhans-75
–
–
–
–
–
–
–
–
–
–
–
Dhans-76
–
–
–
–
–
–
–
–
–
–
–
Dhans-201
+
–
–
–
–
–
–
–
+
+
+
Dhans-220
+
–
–
–
–
–
–
–
–
+
+
Dhans-237
+
–
–
–
–
–
–
–
+
+
+
Dhans-242
+
–
–
–
–
–
–
–
+
+
+
Dhans-246
+
–
–
–
–
–
–
–
+
+
+
Dhans-255
+
–
–
–
–
–
–
–
–
–
–
Dhans-262
+
–
–
–
–
–
–
–
+
+
+
Dhans-265
+
–
–
–
–
–
–
–
+
+
+
Dhans-274
+
–
–
–
–
–
–
–
+
+
+
Dhans-276
+
–
–
–
–
–
–
–
–
+
+
C. ortho = Candida orthopsilosis, C. glab = Candida glabrata, C. trop = Candida tropicalis, W. anom = Wickerhamomyces anomalus
+ = Killer positive, presence of an inhibition zone, – = Killer negative, no inhibition zone observed
v = Killer activity variable

49

50
Candida glabrata, the second most common Candida species isolated from
patients with candidemia (Pfaller et al. 1998), presented an interesting profile. No D.
hansenii strains exhibited killer activity against C. glabrata when assayed at a uniform
20C. Due to a faulty thermostat in our incubator, we incubated the D. hansenii vs. C.
glabrata interaction at 10C for 24 hours before we realized the thermostat flaw and
shifted the plates to 20C for the remaining incubation. Nine strains exhibited killing
activity against this pathogen after five days (Figure 2.2, Table 2.4). However, when
trying to replicate this experiment we obtained a third different profile, which included
strain Dhans-34 presenting mycocin activity contrary to the previous assay. Cold shock
did not alter the killer profile against any other strain from that observed at 20C,
although we observed clearer and larger zones of killing in assays that had undergone a
cold shock. D. hansenii favors lower temperatures than the pathogenic species (Breuer
and Harms 2006), and the cold shock may have disproportionately slowed Candida and
Wickerhamomyces growth relative to D. hansenii, allowing more time for killer toxin
production. C. glabrata is a distant relative to the other yeasts in this study, being closely
related to Saccharomyces cerevisiae (Roetzer et al. 2011). Further study would be
necessary to posit a mechanism for the observed cold shock effect, and to determine
whether it would have any relevance in vivo.
Nevertheless, this presents itself as an interesting research field, due to the
similarities that Candida glabrata possesses with Saccharomyces cerevisiae (Roetzer et
al. 2011). Considering that D. hansenii is highly influenced by higher salt concentrations,
conducting this assay at higher NaCl concentrations would give us a better understanding
of the killing phenotype.
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Figure 2.2 Cold shock killer assay. YPD methylene blue plate agar seeded with
bloodstream isolate of Candida glabrata B9872 and then streaked with strains of
Debaryomyces hansenii. Killer strains (Dhans-237, Dhans-262 and Dhans-201) show a
zone of inhibition after 24 hours of incubation at 10C followed 20C incubation for
seven days, as opposed to Dhans-220 where no inhibition zone is observed.

Killer yeasts, as a self-protection mechanism, are immune to the action of the
toxin they produce (Bussey 1991; Schmitt and Breinig 2006). A killer toxin assay
performed between the D. hansenii strains that exhibited the killer phenotype and the
ones that did not show killing activity revealed that even strains lacking killer activity in
any of our assays possess immunity to the action of the toxins from their own species (see
Table 2.5). In Saccharomyces cerevisiae, in which the killer phenomenon was first
described, a wide range of phenotypes exists: killer strains which both kill and are
resistant to killer toxin (K+R+), susceptible strains which neither kill nor are resistant (KR-), neutral strains which do not kill but are resistant to mycocins (K-R+), and, rarely,

52
“suicidal” strains which kill but possess reduced immunity to their own mycocins (K+
R-) (Polonelli et al. 1991). Thus far we have only observed killer and neutral D. hansenii
strains; increased sampling may reveal further diversity.

Table 2.5 Killer toxin activity of Debaryomyces hansenii killer strains against D.
hansenii non-killer strains
Strains
Dhans-68 Dhans-72 Dhans-75
Dhans-10
–
–
–
Dhans-34
–
–
–
Dhans-45
–
–
–
Dhans-46
–
–
–
Dhans-65
–
–
–
Dhans-201
–
–
–
Dhans-220
–
–
–
Dhans-237
–
–
–
Dhans-242
–
–
–
Dhans-246
–
–
–
Dhans-255
–
–
–
Dhans-262
–
–
–
Dhans-265
–
–
–
Dhans-274
–
–
–
Dhans-276
–
–
–
– = Killer negative, no inhibition zone observed

Dhans-76
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

Debaryomyces hansenii possesses three plasmids: pDHL1 pDHL2 and pDHL3
(Gunge et al. 1993). Plasmid pDHL1 is highly homologous to the plasmid pGKL1
present in Kluyveromyces lactis, which encodes a protein that is the source of the killer
phenotype (Fukuda et al. 1997). Killer yeasts can be cured of plasmid-encoded killer
phenotype by a series of methods that include, but are not limited to, exposure to high
temperatures, ultraviolet light and cycloheximide (Santos et al. 2002). To determine
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whether the killer activity of any D. hansenii strain was encoded on a plasmid, strains
were grown with cycloheximide to eliminate cytoplasmic plasmids. Attempts to grow D.
hansenii in a media containing cycloheximide were unsuccessful as a result of protein
biosynthesis inhibition caused by cycloheximide. Alternative treatment in effort to cure
Debaryomyces hansenii’s plasmid with cycloheximide was ineffective (see Figure 2.3).
Our results concur with those of Buzzini and Martini (2000) and Santos (2002)(Buzzini
and Martini 2000; Santos et al. 2002), in which treated Debaryomyces hansenii showed
no reduced activity during killer activity assays on methylene blue plates seeded with a
susceptible species (e.g. Candida tropicalis). Killer strains retaining the killer phenotype
after treatment suggest that the killer phenotype is not associated with the presence of a
plasmid. Further tests could be performed to ensure absence of plasmids in treated cells;
however, all available evidence to date supports the hypothesis of a chromosomal
location for D. hansenii mycocins-encoding gene(s).
Significantly, studies on killer and susceptible yeasts show that strain sensitivity
can be influenced, among other things, by the nature of the cell wall and physiological
niche (Hodgson et al. 1995). Considering Candida as an opportunistic pathogen, but also
a commensal organism of the human microbiota, virulence and other physiological
parameters differ between isolates. The correlation, if any, between virulence in a human
host and resistance or susceptibility to killer toxins remains unknown. Recent
bloodstream isolates such as C. albicans B1783 and B4549 might be expected to be more
aggressive and robust than C. albicans SC5314, which has been subcultured for 30+
years since its original isolation from a patient with disseminated candidiasis. The
inability of any of our D. hansenii killer strains to kill the bloodstream C. albicans (and
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the ability to kill SC5314) demonstrate clearly the need to screen a broad range of
potentially susceptible isolates as well as killer isolates. Candidemia is a serious lifethreatening infection that can affect the brain, heart and bones (Pappas 2006), against
which new therapeutic options are desperately needed. Further sampling may reveal
strains or combinations of strains of killer yeasts with greater efficacy against pathogenic
Candida, while purification of the mycocins(s) from D. hansenii and characterization of
the mode of action may yield a usable antimycotic agent.
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Figure 2.3 Plasmid-curing killer assay. YPD methylene blue plate agar seeded with
Candida tropicalis NRRL-10985 and cycloheximide at concentrations of 1 mg ml-1 (a)
and 10 mg ml-1 (b), subsequently streaked with killer strains of Debaryomyces hansenii
show a zone of inhibition after 24 hours of incubation at 20C.
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Chapter 3
Towards understanding the genetic basis of Debaryomyces hansenii
killer toxin
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3.1 Abstract
Yeasts can produce toxic proteins or glycoproteins, i.e. “mycocins” or “killer
toxins”, which are able to kill sensitive yeast species. The production of mycocins, first
discovered in Saccharomyces cerevisiae, is a widespread phenomenon among various
yeast genera. Debaryomyces hansenii is one of the most halotolerant yeast species, hence
its association with preserved and fermented foods. Strains of D. hansenii have been
shown to kill potentially pathogenic yeasts, including strains of Candida albicans,
Candida glabrata, Candida tropicalis, and Wickerhamomyces anomalus at optimum
conditions of 20C and pH 4.5. The genetic basis and mechanism of action of this
toxin(s) are unknown. Cycloheximide treatment of D. hansenii prior to or during killer
activity assays on methylene blue plates seeded with Candida tropicalis does not reduce
mycocin activity, suggesting that the toxin is not cytoplasmically-encoded, as are several
characterized yeast killer toxins, but chromosomal. To understand the nature of these
toxins, 2x250 paired end Illumina sequencing, averaging 100x coverage (range: 48x 145x), was performed on 7 killer and 3 non-killer strains of Debaryomyces hansenii
previously isolated from different types of cheese. Numerous differences between D.
hansenii strains were identified that may account for the difference in toxicity. Genome
analysis detected 48 DNA regions, ranging from 31-3434 bp, unique to all sequenced
killer strains and missing from non-killer strains, and 32 regions present in all non-killers
and missing from killer strains. Five different regions have been chosen for their possible
killer toxin role, including predicted members of the ABC-ATPase and major facilitator
superfamilies, cytochrome P450s, and interestingly, a multidrug resistance protein.
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Primers were designed and construction of a mutant has begun so as to be one step
closer to understanding the relationship between these regions and the killer toxin
production.

3.2 Introduction
The killer phenomenon among yeasts is fairly common, having been reported in
more than 90 species, across more than 20 genera (Walker et al. 1995; Young and Yagiu
1978). Killer yeasts produce toxic proteins that are able to kill susceptible species. The
genetic basis of these toxins can be encoded on chromosomal genes or in the cytoplasm
as dsRNA virus-like particles or linear dsDNA plasmids (Magliani et al. 1997). The
modes of action to achieve the lethal effect vary and, usually, as a self defense
mechanism they possess intrinsic immunity to the action of their own mycocin (Schmitt
and Breinig 2002). However, there exist situations where mycocin concentration prevails
and this immunity is overcome; so called suicidal mutants (K+ R–) (Polonelli et al.
1991). Young stated that while all killer systems vary, they have a proteinaceous
compound crucial to the killer activity that is common among them, and yeasts from the
same species can produce various toxins with distinctive modes of action (Young and
Yagiu 1978).
The first requirement to kill a susceptible organism is commonly a cell wall
receptor on the sensitive cell that interacts with the killer toxin, usually chitin, -glucans
or mannoproteins, and suggestions exist about the existence of a second receptor on the
plasma membrane that facilitates absorption (Magliani et al. 1997; Schmitt and Breinig
2006). Subsequently, they can achieve the lethal effect by different biological pathways.
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K1 and K2 toxin produced by Saccharomyces cerevisiae induce changes in the
permeability of the membrane; by forming ion channels an uncontrolled leakage of
protons, potassium ions, amino acids and ATP molecules will occur causing cell death
(Marquina et al. 2002). Alternatively, the S. cerevisiae K28 toxin releases a signal that
results in inhibition of DNA synthesis, which produces the lethal effect (Liu et al. 2015).
Several authors explain the killer activity that Kluyveromyces lactis exhibits towards
Saccharomyces cerevisiae as an attack on the tRNA leading to cell death (Frohloff et al.
2001; Jablonowski and Schaffrath 2007; Jablonowski et al. 2006). Additionally, KP4
toxin produced by Ustilago maydis inhibits growth and division of susceptible cells by
blocking calcium uptake (Gage et al. 2001).
Debaryomyces hansenii is a haploid yeast that reproduces by multilateral budding
(Breuer and Harms 2006) and is an extremophile, one of the most halotolerant yeast
species, growing in media containing up to 4M NaCl (Breuer and Harms 2006). It was
originally isolated from saline environments (Kumar et al. 2012) and is the most common
yeast found in cheese (Banjara et al. 2015) and in dry–cured meat products (Andrade et
al. 2009). D. hansenii can also be found in other environments with low water activity;
hence its association with soil, fruits, wine and beer (Breuer and Harms 2006; Kumar et
al. 2012).
Debaryomyces hansenii exhibits the killer phenotype against strains of Candida
albicans and Candida tropicalis in vitro (Banjara et al. 2016) and it has been found to
tolerate killer toxins from Kluyveromyces lactis, Candida zeylanoides and Trichosporon
cutaneum (Fukuhara 1995; Nout et al. 1997). The genetic basis of the killer activity in
Debaryomyces hansenii remains unexplored. Gunge reported the presence of three
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plasmids, pDHL1, pDHL2 and pDHL3, in D. hansenii (Gunge et al. 1993), and
discovered that plasmid pDHL3 is fundamental for pDHL1 and pDHL2 replication
(Fukuda et al. 1997). Killer yeasts can be cured of plasmid-encoded killer phenotype by a
series of methods that include exposure to high temperatures, ultraviolet light and
cycloheximide (Fukuhara 1995; Santos et al. 2002). Assays performed on D. hansenii
strains suggest that the killer character in D. hansenii is not cytoplasmically encoded, but
chromosomally. Corredor and colleagues reported high genome variability between
strains of D. hansenii based on chromosomal rearrangements and repeated and deleted
sequences (Corredor et al. 2003), and Banjara’s work agrees in so far as D. hansenii
isolates from cheese showed consistent, reproducible variation in killer toxin activity
(Banjara et al. 2016).
Santos and Marquina (Santos et al. 2002) described the killer toxin produced by
Debaryomyces hansenii as a low molecular weight secreted protein, and identified 16-D-glucan as the cell wall binding site for this killer toxin. It is unknown if additional
toxins may exist and how the killing mechanism of these toxins is achieved. Furthermore,
Marquina and colleagues (Marquina et al. 2001), and Banjara’s work revealed that the
killer activity is pH and temperature dependent, with optimum conditions at 20C and pH
4.5 (Banjara et al. 2016).
It is evident that more research is needed to understand the mechanisms by which
Debaryomyces hansenii mycocins achieve the lethal effect, so as to take advantage of its
full biotechnological potential. In this study we intend to explore the genome so as to be
able to look for possible regions or genes that could be responsible for toxin production.
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3.3 Materials and Methods
Organisms, growth media and culture conditions
YEPD rich media (1% yeast extract, 2% peptone, 2% dextrose) at room
temperature was used to grow 10 selected Debaryomyces hansenii strains – seven killer
and three non-killer – previously isolated from different type of cheeses (Banjara et al.
2016). D. hansenii strains have been deposited at the CBS-KNAW Fungal Biodiversity
Centre – an institute of the Royal Netherlands Academy of Arts and Sciences (see Table
3.1 for Debaryomyces hansenii strains and accession numbers).

DNA isolation
High quality DNA extraction for sequencing of Debaryomyces hansenii strains,
and for amplification of the Candida albicans hexokinase gene (HEX1) was
accomplished using a modified version of the QIAGEN Genomic Tip 100/G and
QIAGEN buffer methodology (QIAGEN, Germantown, MD). The yeast protocol from
the QIAGEN Genomic DNA Handbook was followed with the additional use of 65–70C
incubation while pelleting, and the addition of beads, sand and sonication in the protease
pelleting step to increase yield. DNA extraction for PCR assays was performed using a
modified version of the Bust n’ Grab method (Harju et al. 2004), in which the freezing (80C for 5 minutes) and heating (95C for 1 minute) steps were repeated twice.
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Genome sequencing and analysis
Illumina sequencing, 2 x 250 paired end reads to an estimated 50X coverage, was
performed on 7 killer and 3 non-killer, arbitrarily selected, Debaryomyces hansenii
strains at Michigan State University, Research Technology Support Facility (RTSF).
Sequences have been deposited with the National Center for Biotechnology Information
(Table 3.1). Quality controlled reads were assembled with SPAdes (Bankevich et al.
2012) version 3.1.0 with kmers 21, 33, 55, and 77. Scaffolds longer than 1 kb were
retained for downstream analysis. Using core eukaryotic genes, all genomes were
estimated to be >94.35% complete (Parra et al. 2007). Genomes were compared in a
pairwise fashion using Mugsy (Angiuoli and Salzberg 2011). Outputs from Mugsy were
parsed with custom perl scripts to identify genome regions exclusive to killer or nonkiller strains. The Candida genome database (http://www.candidagenome.org), NCBI
(http://www.ncbi.nlm.nih.gov), and Génolevures (Sherman et al. 2009) were used to
assign putative functions to sequences of interest.
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Table 3.1 Debaryomyces hansenii strains, killer toxin activity, accession numbers
and source of isolation.
Strain ID

CBS accession BioSample
number

Cheese

Objects

Killer
Activity

Dhans-68

14260

SAMN04420253 Queso Authentico

–

Dhans-72

14261

SAMN04420254 Hennings Colby

–

Dhans-76

14269

SAMN04420255 Cheddar (Black Creek

–

Smooth and Creamy)
Dhans-220

14262

SAMN04420256 Italian Bel Paese

+

(Galbani)
Dhans-237

14264

SAMN04420257 Italian Bel Paese

+

Dhans-242

14266

SAMN04420258 Parmesan (Reggiano)

+

Dhans-246

14265

SAMN04420259 Raclette (Grand Cru)

+

Dhans-255

Provolone Cheese

–1

(Dilusso’s Wisconsin)
Dhans-274

14267

SAMN04420260 Blue cheese (Roth Kase

+

Minis)
Dhans-276

14268

SAMN04420261 Blue cheese (Roth Kase

+

Minis)
+ = Killer positive, presence of an inhibition zone
– = Killer negative, no inhibition zone observed
1

Dhans-255 was originally identified as killer (Banjara et al. 2016), but was not observed

to kill in our assays. It also exhibited morphological variation from the other D. hansenii
strains and the DNA sequence quality was low, so this strain was excluded from further
analysis and was not deposited with CBS or NCBI.
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Construction of the gene knockout cassettes
Polymerase chain reaction (PCR) was used to assemble gene knockout cassettes
by fusing noncoding DNA upstream and downstream of the gene of interest (genes
unique to either killer or non-killer strains) with DNA encoding the Candida albicans
HEX1 gene, following the protocol outlined by Hallen and Trail (2008). The 1000 bp
upstream and downstream of genes of interest (Table 3.2) were downloaded from
Génolevures (Sherman et al. 2009) and trimmed as necessary to ensure these regions
contained no predicted proteins. Primers were designed using Lasergene Version 12.0
(DNASTAR, Madison, WI) (Table 3.4), and the presence of primer sequences in the
relevant D. hansenii strains (killer or non-killer, as appropriate) was confirmed using
SeqMan NGen version 12.0 (DNASTAR). The 5’ ends of primers nearest to the targeted
gene (upstream reverse primers and downstream forward primers; Table 3.4 and Figure
3.2) included an additional 17 to 23 nucleotides complementary to the C. albicans HEX1
gene.
PCR reactions for amplification of noncoding DNA regions (upstream and
downstream) were performed with the following conditions: initial denaturation at 95 °C
for 3 min, followed by 34 cycles at 95°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min,
and a final extension step of 72°C for 5 min. Each reaction contained 12.5 l of Maxima
Hot Start Green master mix DNA polymerase (ThermoScientific), 2 l of each
oligonucleotide primer, 7.5 l of molecular biology-grade water and 1 l DNA template
for a final volume of 25 l. PCR was performed on Dhans-237 and Dhans-274 to amplify
regions unique to killer strains, and on Dhans-68 and Dhans-76 for regions unique to
non-killers. HEX1 was amplified from C. albicans SC-1543 using 0.25 l of TaKaRa Ex
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Taq polymerase, 5 l of 10X Ex Taq Buffer (Mg plus), 4 l of dNTP Mixture, 5 l
2+

each of primers 1 and 2 (Table 3.4), 28.75 l of molecular biology-grade water, and 2l
DNA template for a final volume of 50 l), using the amplification conditions described
above.

Table 3.2 Chosen genes and their predicted function.
ID of Chosen Regions

Primer ID

Conserved Domains

DEHA2D01056g

D1056

The Major Facilitator Superfamily

DEHA2G14916g

DoubleGene

Multidrug resistance protein

DEHA2G14894g

DoubleGene

ABC-2 type transporter

DEHA2E00220g

E220

No prediction

DEHA2G00110g

G110

Cytochrome P450

ID of chosen regions is the gene ID from Génolevures, and is read as follows:
DEHA2D01056g is Debaryomyces hansenii (strain CBS 767), sequence build 2,
chromosome D, gene 01056, from genomic DNA. Primer ID is derived from the
chromosome and gene number, except for “DoubleGene”: genes G14916 and G14894 are
adjacent, so primers were designed upstream and downstream of the pair, to knock both
out simultaneously.

PCR products from the upstream region and the HEX1 gene were combined with
an additional round of PCR using primer 1 and upstream forward primers (primers 5, 9,
13, and 17). Downstream region and HEX1 gene were combined with an additional round
of PCR using primer 2 and downstream reverse primers (8, 12, 16, and 20). Fusion of the
upstream-HEX1 and downstream-HEX1 was achieved using primers 5 and 8, using an
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adaptation of the protocol for Expand Long-Template Polymerase (Roche Applied
Science, Indianapolis, IN), as outlined in Table 3.3. PCR mixture for amplification of
Candida albicans HEX1 gene and for assembling the knockout cassette contained 0.25 l
of TaKaRa Ex Taq polymerase, 5 l of 10X Ex Taq Buffer (Mg2+ plus), 4 l of dNTP
Mixture, 5 l of each oligonucleotide primer, 28.75 l of molecular biology-grade water,
and 2l DNA template for a final volume of 50 l. Bands were purified as needed using
the Wizard® SV Gel and PCR Clean-Up System (Promega, Madison, WI) following
manufacturer’s instructions. All amplifications were carried out on a T100 Thermal
Cycler (Bio-Rad, Hercules, CA, USA) and PCR products were visualized by ethidium
bromide staining on an agarose gel. Figure 3.2 shows a schematic of this protocol.

Table 3.3 PCR expansion protocol
PCR stage

Temperature

Time

Denaturation

95C

4 min

Denaturation

95C

30 sec

Annealing

52C

30 sec

Extension

72C

2:30 min

GOTO step 2

10 cycles

Denaturation

95C

30 sec

Annealing

52C

30 sec

Extension

72C

2:30 min +5 s per cycle

GOTO step 6

25 cycles

Extension

72C

7:00 min

Hold

4C
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3.4 Results and Discussion
High quality DNA from Debaryomyces hansenii killer (Figure 3.1) and non-killer
strains (not shown) was successfully extracted and used for whole genome sequencing.

Figure 3.1 DNA isolation. High-quality DNA extraction from Debaryomyces hansenii
strains. From left to right, killer strains Dhans-242, Dhans-220, Dhans-274, Dhans-276,
Dhans-265 (not sequenced), Dhans-246, Dhans-255 and Dhans-237.

Genome analysis identified 48 DNA regions unique to all sequenced killer strains
and missing from non-killer strains, and 32 regions present in all non-killers and missing
from killer strains, ranging from 31-3434 bp. While single nucleotide polymorphisms
(SNPs) and other genetic features may influence killer status, we chose to focus on larger
differences involving gene presence and absence. The Candida genome database
(http://www.candidagenome.org) was used to find the designated regions where the
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identified sequence was localized. Subsequently, NCBI (http://www.ncbi.nlm.nih.gov)
was used to find the predicted functions or conserved domains of the sequences (Table
3.2). We found four distinct regions that look promising, that include a predicted member
of the major facilitator superfamily (MFS), which are a group of transporters (Pao et al.
1998); an ABC-2 type transporter (Reizer et al. 1992); cytochrome P450 which is
involved in the production and degradation of toxic compounds (Ogu and Maxa 2000),
and a multidrug resistance protein that is known to be involved in the export of toxins
(Blackmore et al. 2001). Additionally, we selected one gene that had no predicted
function and appears to have no homolog in the databases outside of D. hansenii.
Génolevures provided the genetic elements of the chosen sequences (Sherman et al.
2009). Finally, primers were built for the chosen regions using DNASTAR software
(Table 3.4) and overlaps were built to complement the HEX1 gene from Candida
albicans, which allows them to fuse in a separate PCR reaction.
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Table 3.4 PCR primers designed with DNASTAR® for gene knockout.
Primer
no.
1

Primer ID

Sequence

Hex1XformF

5’-cccgatccttggtgctc-3’

2

Hex1XformR

5’-ccccttccttaatttgtgtttgat-3’

3

Hex1InternalF

5’-ccaggggatatgatgttgtag-3’

4

Hex1InternalR

5’-ctgtggagctgggagtatttc-3’

5

E220UpF

5’-acgcagggtaaagtatcaatcca-3’

6

E220UpR

5’-atcaaacacaaattaaggaaggg_gtgcgcaagccaaaagtgt-3’

7

E220DownF

5’-gagcaccaaggatcggg_tctacgaaatgaatgaccta-3’

8

E220DownR

5’-aatatgtgttctaaccttgatg-3’

9

G110UpF

5’-ctattctccattcgcatcacaac-3’

10

G110UpR

5’-atcaaacacaaattaaggaagggg_ccagaaaaagggcagcatagt-3’

11

G110DownF

5’-gagcaccaaggatcggg_cgcgccgcatcaacaga-3’

12

G110DownR

5’-aggcaacgagtcccgaacataa-3’

13

D1056UpF

5’-aagccagggatgttagg-3’

14

D1056UpR

5’-atcaaacacaaattaaggaagg_ggcggctgctgggtttat-3’

15

D1056DownF

5’-gagcaccaaggatcggg_atattaactaaagccgcagagact-3’

16

D1056DownR

5’-aaggggatatgaataacagacaac-3’

17

DoublegeneUpF

5’-gaagccggacagaaggtaga-3’

18

DoublegeneUpR

5’-atcaaacacaaattaaggaagggg_tatatgttttaatcggagaa-3’

19

DoublegeneDownF

5’-gagcaccaaggatcggg_taaaatcggatgcaataagaaatg-3’

20

DoublegeneDownR

5’-aaggcgctcaatccaactc-3’

Bold segments in the UpR and DownF primers are complementary to the HEX1 gene
from Candida albicans.
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Step 1

Step 2

Figure 3.2 Schematic of PCR-based transformation. Amplifying noncoding DNA,
both upstream and downstream, of the gene of interest will result in the construction of
E220 mutants. The PCR products of the upstream and downstream regions have
overlaps built onto the primers of the HEX1 gene allowing them to fuse on an additional
round of PCR. A separate PCR on Candida albicans results in amplification of the HEX1
gene. An additional PCR is used to fuse together the three product: upstream,
downstream and HEX1. E220 is replaced by double-crossover integration of the HEX1
gene into the homologous portion of the genome.
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Using Candida albicans HEX1 gene as a selectable marker will allow us to
identify the transformants by their color on CHROMagar™ Candida (Niimi et al. 2001):
green colonies for colonies expressing C. albicans hexokinase, and purple for wild-type
D. hansenii. Yeast transformations are usually performed using antibiotic resistance
markers (Kaster et al. 1984). However, using hygromycin B as a resistant marker in
yeasts is typically difficult. Chand-Goyal and Eckert (1996) found that D. hansenii is
resistant to the antibiotic and were not able to transform the yeast (Chand-Goyal and
Eckert 1996). Nonetheless, Ricaurte (1999) found strains of D. hansenii that were
susceptible to 100 g/ml of Hyg and successfully transformed the yeast (Ricaurte and
Govind 1999). Effective transformation of D. hansenii using C. albicans HEX1 gene as a
marker will be a novelty and will make transformations of non-albicans Candida and D.
hansenii strains uncomplicated due to color identification.
Upstream and downstream regions for the five genes (four genetic regions) we
selected have all been amplified from the appropriate killer or non-killer D. hansenii
strains, and HEX1 has been amplified from C. albicans. To construct the transformation
cassette, PCR products from the upstream and downstream regions were amplified
together with the HEX1 PCR product from C. albicans. Reactions were performed in
which all three products (upstream, downstream and HEX1), were present, and in which
only two products were present (upstream and HEX1, downstream and HEX1). We have
assembled the transformation cassette for E220 (predicted protein of unknown function),
amplifying the upstream and the downstream region from Debaryomyces hansenii strain
Dhans-68. The PCR product of the Hex1 gene has a size of 1,686 bp, the upstream
product is 507 bp and the downstream product is 423 bp. Using a GeneRuler 1kb Plus
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DNA Ladder from Thermo Scientific, we estimated the size of the products. C.
albicans Hex1 gene estimate size is around 2,000 bp, the upstream region is around 500
bp and the downstream region is around 400 bp (Figure 3.3). Two separate PCR
reactions were done to combine the upstream region with the Hex1 gene and the Hex1
gene with the downstream region. An additional PCR fused the last two products so as to
incorporate the Hex1 gene with the upstream and downstream. This final product
presented a size of around 3,000 bp, which is congruent with the expected outcome of
2,616 bp (Figure 3.4).

3.5 Future Directions
Experiments are underway to incorporate the transformed DNA into a cell. We
are following an adaptation of Hallen-Adams et al. 2011, where the first step is to have
enzymes destroy the cell walls of the yeast. Subsequently, 30% PEG 8000 and sorbitol
solutions will force the DNA into the cell where, in some cells, it will integrate into the
nucleus. A high sugar treatment for 24 hours will allow the cell walls to re-form and
plating in CHROMagar™ will allow us to identify transformed colonies by their green
color (Hallen-Adams et al. 2011).
Preliminary results show that using a high sugar solution results in an excessive
amount of yeast recovery, and YEPD media seems to be more adequate for yeast cells
regeneration. Additionally, a spread plate technique (100 l) in CHROMagar™ results in
a complete growth of the yeast in the plate, where isolation of a single colony is
impossible. A streak plate technique has shown to be more adequate for isolation of
colonies. If green colonies are found the next step will be to confirm the presence of the
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HEX1 gene performing a PCR reaction with primers 3 and 4, and using up- and
downstream primers to confirm the presence of the transformed DNA. Furthermore,
southern blot will help us to confirm the presence of specific DNA segments in our
samples. If green colonies were not present, electroporation would be our next go to
transformation protocol for incorporation of the construct into the cell.
Once the deletion/insertion of genes is confirmed, killer assays will be performed
against Candida albicans and Candida tropicalis. These assays will help us establish the
relationship between the gene of interest and the killer toxin activity. If deleting a gene on
a killer strain results in the absence of the killer phenotype, this suggest that the gene
deleted is somehow involved with the killer toxin production. Studying the genetic basis
of these toxins allows us to understand how the killing mechanism works, and could even
tell us the gene or genes responsible, if any, for the toxin production.
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Figure 3.3 PCR products. A 1kb Plus DNA Ladder (1) was used to determine the size
of the products. Candida albicans HEX1 gene (2 and 3) is close to ~1,686 bp. The
upstream (4) and downstream (5) regions of strain Dhans-68 have a size of ~507 and
~423 bp respectively. Lane 6 shows the water control.
1

2

3

Figure 3.4 Gene replacement cassette. A 1kb marker (1) was used to determine the size
of the products. Lane 2 shows the product from the Dhans-68 transformation (~3k bp)
and lane 3 represents the water control.
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